更新于：2024-06-29
Benoxinate Hydrochloride
盐酸奥布卡因
更新于：2024-06-29
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1966-06-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H29ClN2O3 |
InChIKeyPRGUDWLMFLCODA-UHFFFAOYSA-N |
CAS号5987-82-6 |
关联
9
项与 盐酸奥布卡因 相关的临床试验Preservative-free Topical Anesthetics for the Management of Postoperative Pain Following Photorefractive Keratectomy
Hemodynamic Response Of Premature Brain To Pain During Retinopathy Of Prematurity Screening: A Randomized Controlled Trial
Effect of Benoxinate Hydrochloride Eye Drops on The Premature Infant Pain Profile Score During Retinopathy of Prematurity Screening
100 项与 盐酸奥布卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥布卡因 相关的专利（医药）
登录后查看更多信息
308
项与 盐酸奥布卡因 相关的文献（医药）2024-03-01Canadian journal of psychiatry. Revue canadienne de psychiatrie
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
Article
作者: Jutras-Aswad, Didier ; Bahji, Anees ; Bastien, Gabriel ; Le Foll, Bernard ; Lim, Ron ; Choi, JinCheol ; Bach, Paxton ; Socias, M Eugenia
Background:
Prescription-type opioid use disorder (POUD) is often accompanied by comorbid anxiety, yet the impact of anxiety on retention in opioid agonist therapy (OAT) is unclear. Therefore, this study investigated whether baseline anxiety severity affects retention in OAT and whether this effect differs by OAT type (methadone maintenance therapy (MMT) vs. buprenorphine/naloxone (BNX)).
Methods:
This secondary analysis used data from a pan-Canadian randomized trial comparing flexible take-home dosing BNX and standard supervised MMT for 24 weeks. The study included 268 adults with POUD. Baseline anxiety was assessed using the Beck Anxiety Inventory (BAI), with BAI ≥ 16 indicating moderate-to-severe anxiety. The primary outcomes were retention in assigned and any OAT at week 24. In addition, the impact of anxiety severity on retention was examined, and assigned OAT was considered an effect modifier.
Results:
Of the participants, 176 (65%) reported moderate-to-severe baseline anxiety. In adjusted analyses, there was no significant difference in retention between those with BAI ≥ 16 and those with BAI < 16 assigned (29% vs. 28%; odds ratio (OR) = 2.03, 95% confidence interval (CI) = 0.94–4.40; P = 0.07) or any OAT (35% vs. 34%; OR = 1.57, 95% CI = 0.77–3.21; P = 0.21). In addition, there was no significant effect modification by OAT type for retention in assigned ( P = 0.41) or any OAT ( P = 0.71). In adjusted analyses, greater retention in treatment was associated with BNX (vs. MMT), male gender identity (vs. female, transgender, or other), enrolment in the Quebec study site (vs. other sites), and absence of a positive urine drug screen for stimulants at baseline.
Conclusions:
Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.
Clinical Trial Registration:
This study was registered in ClinicalTrials.gov (NCT03033732).
2024-03-01European journal of ophthalmology
Topical anesthesia versus topical and subconjunctival anesthesia combined in diabetic retinopathy photocoagulation
Article
作者: Fragiotta, S ; Mafrici, M ; Lorenzi, U ; Toscani, L ; Tarsitano, M G
Purpose:
comparison between two anesthetic techniques on the ability to reduce pain during panretinal photocoagulation (PRP) treatment.
Methods:
Observational retrospective single center study. Medical charts of patients who underwent PRP for proliferative diabetic retinopathy were revised. Patients were included if they had the first eye treated with oxybuprocaine hydrochloride drops, and in case of severe pain, the fellow eye received topical anesthesia in combination with 2% subconjunctival lidocaine. The groups were compared for pain perception using an analog visual scale (VAS), number of laser spots, number of interruptions, and laser session duration.
Results:
Forty-two eyes of 21 patients (mean age: 58.3 ± 7.6 years) were analyzed. The mean number of laser spots was significantly higher under combined anesthesia (+84.2 ± 155.9 spots, p = 0.01), with a reduced time for laser execution (−2.5 ± 3.12, p = 0.0008). The use of combined anesthesia significantly decreased the number of interruptions (−40.8%, p < 0.0001) into a single session. On the pain grading scale, the pain perception was significantly lower in the combined anesthesia group ( p < 0.0001). In eyes receiving topical anesthesia the treatment was stopped for pain in 5 eyes (23.8%), while 5 eyes under combined anesthesia presented subconjunctival hemorrhage (23.8%).
Conclusion:
Using combined anesthesia in patients subjected to PRP appeared to reduce pain perception limiting the treatment duration and the interruptions for pain without significant complications. Further studies on a larger scale would be desirable to replicate such findings and standardize the analgesic procedures in ophthalmology.
2024-01-01Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Investigating fluorogenic labelling of amine coupled with first-order derivative spectrofluorimetry as a versatile analytical methodology: Application to estimation of benoxinate in its eye drops
Article
作者: Abo El Abass, Samah ; Aboshabana, Rasha ; Samir Elama, Heba ; Elmansi, Heba
In this research, fluorogenic labelling followed by applying first-order derivative spectrofluorimetry for the developed fluorophore is discussed as an alternative, sensitive and selective analytical approach. Benoxinate, containing a primary amine and fluorescamine reagent were selected for the study. Then the proposed methodology relies on the reaction between the primary amine in benoxinate with fluorescamine that selectively reacts with primary amines to develop highly fluorescent products. The fluorescamine-benoxinate developed fluorophore is identified by its sharp first-order derivative peak at 465 nm following excitation at 386 nm in borate buffer, pH 8. The optimum reaction conditions were ascertained. Following ICH validation guidelines, the first order derivative of the relative fluorescence intensity for the developed fluorophore was linearly related to benoxinate concentration and ranged from 20.0 to 200.0 ng/mL with a detection limit of 3.36 ng/mL and a quantitation limit of 10.19 ng/mL, moreover, satisfying accuracy and precision values were obtained upon statistical analysis of results. The offered analytical method was successfully applied to quantify benoxinate in raw material and Benox® eye drops as a direct application to a commercial formulation.
100 项与 盐酸奥布卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多泪 | 日本 | 1972-12-26 | |
| 麻醉 | 日本 | 1966-06-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin | 壓獵願願範齋繭膚顧築(蓋醖廠觸鹽廠襯鏇觸襯) = 窪鹽衊廠壓繭膚網醖製 網選衊遞鏇艱選衊築簾 (願窪築簾壓糧醖壓遞夢, 膚選顧觸積構繭廠繭構 ~ 膚襯獵製顧淵選範觸艱) 更多 | - | 2024-04-23 | ||
N/A | 50 | Tetracaine/Oxybuprocaine | 衊衊繭淵艱願鹽艱築積(淵築簾網襯遞壓窪觸築) = 餘襯製淵襯簾簾壓鬱構 築膚製製壓齋膚鏇廠膚 (鹹積簾壓構願鹹構鑰齋 ) | 积极 | 2006-05-01 | ||
衊衊繭淵艱願鹽艱築積(淵築簾網襯遞壓窪觸築) = 衊範簾觸遞窪齋鑰淵顧 築膚製製壓齋膚鏇廠膚 (鹹積簾壓構願鹹構鑰齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用